Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial
Author
Subbiah, VivekGainor, Justin F
Oxnard, Geoffrey R
Tan, Daniel S W
Owen, Dwight H
Cho, Byoung Chul
Loong, Herbert H
McCoach, Caroline E
Weiss, Jared
Kim, Yu Jung
Bazhenova, Lyudmila
Park, Keunchil
Daga, Haruko
Besse, Benjamin
Gautschi, Oliver
Rolfo, Christian
Zhu, Edward Y
Kherani, Jennifer F
Huang, Xin
Kang, Suhyun
Drilon, Alexander
Date
2021-06-18Journal
Clinical Cancer ResearchPublisher
American Association for Cancer ResearchType
Article
Metadata
Show full item recordAbstract
We report the intracranial efficacy of selpercatinib, a highly potent and selective RET inhibitor, approved in the United States for RET fusion-positive non-small cell lung cancers (NSCLC).Rights/Terms
©2021 American Association for Cancer Research.Keyword
LIBRETTO-001 TrialRET fusion-positive NSCLC
selpercatinib
Carcinoma, Non-Small-Cell Lung--drug therapy
Identifier to cite or link to this item
http://hdl.handle.net/10713/16059ae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.CCR-21-0800
Scopus Count
Collections
Related articles
- Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.
- Authors: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V
- Issue date: 2020 Aug 27
- Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial.
- Authors: Minchom A, Tan AC, Massarelli E, Subbiah V, Boni V, Robinson B, Wirth LJ, Hess LM, Jen MH, Kherani J, Olek E, McCoach CE
- Issue date: 2022 Feb 3
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
- Authors: Gainor JF, Curigliano G, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V
- Issue date: 2021 Jul
- Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
- Authors: Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, Davare MA, Gladstone E, Ivanova EV, Henry DN, Kelley EM, Lin M, Milan MSD, Nair BC, Olek EA, Scanlon JE, Vojnic M, Ebata K, Hechtman JF, Li BT, Sholl LM, Taylor BS, Ladanyi M, Jänne PA, Rothenberg SM, Drilon A, Oxnard GR
- Issue date: 2021 Jan 1
- Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers.
- Authors: Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME
- Issue date: 2020 Aug 27